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Abstract
Background: Trichomoniasis, a sexually transmitted disease (STD), is caused by Trichomonas vaginalis in both men
and women. Screening of trichomoniasis is problematic in resource challenged settings as currently available,
inexpensive diagnostic methods are of low sensitivity and/or specificity. In India, National AIDS Control organization
(NACO) recommended syndromic case management (SCM) for treatment. The objective of the present study was to
compare the utility of the NACO-NACP III Algorithms for STI/RTI treatment used by clinicians with PCR based diagnosis.
Methods: Patients visiting Department of Obstetrics & Gynecology, Vardhman Mahavir Medical College and Safdarjung
Hospital, New Delhi from January 2011 to June 2014 were enrolled in the study to compare the diagnostic efficiency of
PCR-based assays against SCM. Based on SCM, patients (n = 820) were treated with antibiotics using pre-packed STI/RTI
kits (sexually transmitted infection/reproductive tract infection; procured by National AIDS Control/State AIDS Control
Society (NACO/SACS), Ministry of Health and Family Welfare, Govt of India.) under National AIDS Control Programme
(NACP III) for syndromic case management (SCM). Ectocervical dry swab samples were also obtained from these
patients and out of that 634 samples were tested by PCR. Total genomic DNA was extracted from these samples and
used as template for PCR amplification using pfoB, gyrA and orf1 gene specific primers for diagnosis of T. vaginalis (TV),
Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) respectively.
Results: Out of 6000 patients who visited OPD, 820 (14 %) female patients reported vaginal discharge and were
recommended antibiotic treatment for one or more pathogens namely, TV, CT, NG and Candida or for co-infection.
On the basis of signs & symptoms and NACO guidelines, the following distribution of various infections was observed:
TV (46 %), CT (20 %), coinfection with TV and CT (12 %), coinfection with CT and NG (11 %), coinfection with TV, CT and
Candida (7 %) and coinfection with TV and NG (2 %). Others were infected with NG alone (1 %), coinfected with TV
and Candida (0.4 %) and 0.3 % were coinfected with CT, NG and Candida. Based on PCR method, 110 (17 %) women
tested positive for one or more of these three pathogens while 524 (83 %) women were negative for any of these
three pathogens but could be positive for other STIs not tested in this study. Since all the patients (634) were given
antibiotics, we estimate that the over-treatment was 85 % while 524 (83 %) patients were also misdiagnosed by SCM.
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Conclusions: The over-treatment and inaccurate diagnosis of pathogens due to subjective judgment based on
syndromic approach in symptomatic women is a large economic wastage and may also contribute towards
increased resistance. The misdiagnosed patients will also serve as a reservoir for transmission of pathogens to
their sexual partner.
Keywords: Trichomoniasis, Syndromic case management, PCR based diagnosis, Misdiagnosis, Overtreatment
Multilingual abstract
Please see Additional file 1 for translations of the ab-
stract into the six official working languages of the
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Background
Trichomonas vaginalis (TV) is a flagellated protozoan
parasite of the genital tract causing trichomoniasis, a
common sexually transmitted infection (STI) affecting
men and women [1, 2]. It is one of the “neglected” STDs
and approximately 50–60 % infections remain asymp-
tomatic [3, 4]. The clinical symptoms of infection in
women include “frothy discharge”, punctate bleeding of
the cervix, often referred to as “strawberry cervix”. The
less specific symptoms of trichomoniasis include vaginitis,
cervicitis, itching, vulval irritation, inflammation, dysuria,
lower abdominal pain (LAP) and infection linked with pel-
vic inflammatory diseases (PID), adverse outcomes of
pregnancy and cervical cancer [5–11]. T. vaginalis infec-
tion also enhances the transmission of human immuno-
deficiency virus (HIV) infection [5, 8]. Symptoms in men
include discharge which may or may not contain signifi-
cant quantities of lymphocytes or red blood cells (RBC),
dysuria, increased urinary frequency or prostatitis [5, 12].
On rare occasions men may have urethral strictures or
epididymitis but the vast majority of men with trichomon-
iasis have no sign or symptoms of infection [13]. The
laboratory diagnosis for trichomoniasis includes rapid cul-
ture, wet mount, rapid antigen immune capillary, nucleic
acid amplification tests (NAATs) and quantitative PCR
(qPCR) based assays [14–17]. The developing countries,
however, rely on SCM as available rapid tests of tricho-
moniasis have low sensitivity and specificity [18, 19]. The
qPCR requires sophisticated laboratory facilities and quali-
fied personnel with expertise who can perform technically
demanding procedures [20, 21]. The culture method, al-
though less expensive and highly specific, is less sensitive,
difficult and takes several days. As test results cannot be
made available immediately, delay and/or failure of the pa-
tient to come back to collect the test report, impede the
treatment initiation [20–22]. Such patients continue to
spread the disease to their sexual partners by serving as
the reservoirs [23–25]. For these reasons, the SCM of
trichomoniasis remains the most feasible option for
clinician in low resource settings. SCM of the disease is
based on the identification of signs and symptoms that
characterize standard clinical symptoms of the disease
so as to predict the likelihood that a patient is infected
with a specific pathogen [17, 18]. Based on the predic-
tion of infection, appropriate treatment is prescribed at
the first visit itself rather than deferring the treatment
until an accurate and confirmed diagnosis is obtained.
In the absence of a proper, inexpensive diagnostic assay
in the resource poor settings, the syndromic approach
takes on greater relevance in controlling the transmis-
sion of STIs and its sequel. However, despite these ad-
vantages, there are several limitations associated with
SCM [26]. As SCM relies on subjective judgment, it may
result in over diagnosis/overtreatment in patients infected
with microbes other than T vaginalis. This may also con-
tribute towards the development of drug resistance against
other STIs [27–29]. Another challenge for controlling
STIs by syndromic approach is mixed infection by more
than one pathogen with similar clinical presentations [30].
Due to the lack of trained personnel, inadequate labora-
tories and infrastructure in several parts of the developing
countries, information regarding the profile of STIs relies
essentially on self-reported or physician-diagnosed STI
and hence prevalence amongst asymptomatic individuals
is unavailable. This contributes to the lack of treatment of
asymptomatic patients, resulting in the spread of the dis-
ease to their sexual partners. In fact, there are no standard
protocols and/or line of treatment that is prescribed for
SCM of trichomoniasis in India. As a result, there is no
consensus on the performance of SCM of T. vaginalis and
reports from different regions carried out on small groups
of patients, fail to provide a clear and consistent evalu-
ation [31–34]. Thus, there is an urgent need to evaluate
the validity of the SCM of T vaginalis infection. Here we
report the results of a detailed comparative study on syn-
dromic and PCR-based laboratory assay for diagnosis of T
vaginalis using 634 clinical samples collected from the De-
partment of Obstetrics & Gynecology, Vardhman Mahavir




The study was carried out as per the institutional ethical
guidelines and approval (ACBR No: F-50-2/Eth.com/AC
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BR/11/2107 and VMMC and Safdarjung Hospital No:
47-11-EC/30/51). Informed written consent from all par-
ticipants involved in the study was obtained. The results
of the study did not influence the treatment.
Enrollment of patients
The patients visiting Department of Obstetrics &
Gynecology of VMMC and gynecology OPD of Safdar-
jung Hospital, New Delhi, from January 2011 to June
2014 were enrolled in this study. Out of 6 000 patients
who visited OPD during this period, ectocervical swab
samples (n = 634) were collected from non-pregnant
women (18 years to ≥ 56 years of age) seeking diagnosis
and treatment of vaginal discharge syndrome (VDS) or
PID. Individuals who were already on antibiotics, preg-
nant, unmarried and females below 18 years of age were
excluded. To confirm non-pregnancy every patient com-
ing to Gynecology OPD was asked about her last men-
strual period. If she was overdue, pregnancy test (urine
based) was conducted in the OPD on the same day.
Specimen collection and processing
A thorough clinical examination including the speculum
examination was done for lesions, warts, ectopic growth
and vaginal/cervical discharge by the attending clinician.
Ectocervical swab samples were collected and placed in
the empty vial (dry swabs) and were kept frozen at −20 °C
until use. Dry swab was incubated in Phosphate Buffered
Saline (PBS, 1 mL) for 10 min at 4 °C, mixed by vortexing
thoroughly to disperse the sample and squeezed. The sam-
ple (400 μl) was centrifuged at 11 000 × g at 4 °C for
10 min and the cell pellet was suspended in 40 μl of PBS
followed by centrifugation at 11 000 × g at 4 °C for 5 min.
Total genomic DNA was isolated essentially as described
earlier from our laboratory for other pathogens [35, 36].
Briefly, the cell pellet was suspended in 40 μl of 1X lysis
buffer containing 50 mM Tris–HCl (pH 7.5), 1 % Triton
X-100, proteinase K (250 μg/ml). The cell suspension was
incubated at 65 °C for 45 min to lyse the cells, followed by
boiling for 10 min at 95 °C after addition of DTT (1 mM).
Sample was then snap-chilled for 5 min followed by
centrifugation at 8 000 × g at 4 °C for 10 min. To the
supernatant, 50 μl of phenol-chloroform-isoamyl alcohol
(25:24:1) was added and the aqueous phase containing
DNA was collected. The nucleic acids were precipitated
by adding 1/10 volume of 3 M sodium acetate (pH 5.2),
glycogen (1μl20mg/ml) and 2.5 volumes of 100 % ethanol.
After incubating at 20 °C for 1-2 h, samples were centri-
fuged at 11 000 × g at room temperature for 10 min and
the nucleic acids pellet was washed with 70 % chilled etha-
nol by centrifugation at 11 000 × g at room temperature
for 5 min. The pellet was air dried at 55 °C before sus-
pending in either 50 μl of TE buffer, pH 7.0 (10 mM Tris
HCl, 1 mM EDTA) or in DNase- and RNase-free water
(Sigma-Aldrich, St. Louis, Mo. W4502). The nucleic acid
samples were stored at 4 °C till further use as template
DNA for PCR assay and clinical evaluation.
PCR amplification
All the clinical samples were analyzed for the presence of
T. vaginalis using in-house developed pfoB PCR assay.
The in-house developed assay was evaluated by composite
reference standard (CRS) method and found to be highly
sensitive, 94.44 (CI 95 % 81.30–99.16) and specific, 99.72
(CI 95 % 98.44–99.95), it can detect up to 25 fg genomic
DNA with remarkable NPV, PPV and Likelihood ratio
(Sonkar et, al. manuscript submitted) and Indian patent
filed and published, Patent application No. 1098/DEL/
2013A, publication date: 03/01/2014) [36]. The diagnosis
of C. trachomatis and N. gonorrhoeae was carried out
using PCR based assay developed earlier [35, 37]. Briefly,
PCR amplification was carried out in 25 μl reaction mix
containing 1X Taq DNA Polymerase, buffer (50 mM
KCl, 10 mM Tris-HCl pH 8.3, 1.5 mM MgCl2), 200 μM
each of the four deoxyribonucleoside triphosphates
(dNTPs) (Bangalore Genei India Pvt. Ltd.), 5pmoles
each of forward and reverse primer, 5 μl of total gen-
omic DNA isolated from clinical sample, 2.0 U of Taq
DNA Polymerase (Bangalore Genei India Pvt. Ltd.).
Each set of PCR assays included a negative control
(sterile water instead of DNA sample) and a positive
control (1 ng of purified genomic DNA of T. vaginalis).
Amplification of T. vaginalis was performed in the
thermal cycler (I cycler, BioRad, USA) using the follow-
ing conditions; 96 °C for 5 min for initial denaturation,
35 cycles of 96 °C for 20 s, 56 °C for 30 s, 72 °C for 25 s
and final extension at 72 °C for 7 min. The amplifica-
tion of C. trachomatis and N. gonorrhoeae was as per
published protocol [35, 37].
Detection of amplified products
The amplicons in 25 μl were analyzed by electrophoresis
on 2.0 % agarose gel and visualized by ethidium bromide
staining and illumination with UV light (LumG Aplegen,
USA). The amplicons from 10 % of the positive samples
were eluted using a DNA elution kit (MDI membrane
Technologies, India), according to the manufacturer′s
instructions and sequenced using forward PCR primers
with Big Dye terminator cycle sequencing kit on 377A
autosequencer (Applied Biosystems, California, USA). The
DNA sequence of the amplified product was compared to
that of known sequence of pfoB, orf1 and gyrA gene for T.
vaginalis, N. gonorrhoeae and C. trachomatis respectively
in the GenBank databases using the BLASTn program
(http://blast.ncbi.nlm.nih.gov) to determine the percent
identity.
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Statistical analysis
The data was plotted and analyzed using the statistical
software package SPSS version 20.
Results
A clinic-based study was carried out in association with
the Department of Obstetrics & Gynecology Department
of VMMC and Safdarjung Hospital gynecology OPD from
January 2011-June 2014. During this period 6 000 patients
visited the OPD out of which 820 (14 %) female patients
with vaginal discharge suspected of infection with T. vagi-
nalis, C. trachomatis, N. gonorrhoeae and Candida were
recruited based on SCM (see Figs. 1 and 2). These 820 pa-
tients were recommended pre-packed STI/RTI antibiotic
treatment kits procured from NACO/SACS, Ministry of
Health and Family Welfare, Govt of India, under the
NACP III for disease management. Ectocervical dry swab
samples were also obtained from these 820 patients out of
which 634 patients were scored in this study. The other
samples could not be included as the symptom descrip-
tions and demographic data were incomplete. Out of 634
samples that were considered positive for one or more
pathogens using SCM approach, PCR based diagnostic
assay showed only 110 samples to be positive for one of
the pathogens, C. trachomatis (CT), N. gonorrhoeae (NG)
and T. vaginalis (TV) or coinfections (Table 1). Since all
the patients (n = 634) were given antibiotics on the basis
of SCM, our results show that a large proportion (85 %) of
the patients were over treated due to lack of accurate and
confirmed diagnosis. When we analyzed the coinfection
status of these samples for TV, CT and NG using SCM ap-
proach, it was observed that 12 % patients were coinfected
with TV, CT and NG while 11 % were coinfected with CT
and NG and 7 % with CT and TV (Table 1). According to
SCM, infection with NG was low in general (less than
1 %) and most of the patients were co-infected with TV
(1 % of total patients). To differentiate between T. vagina-
lis and Bacterial vaginosis amongst the suspected cases
with vaginal discharge (n = 634), the color, smell and vis-
cosity of discharge were the main differentiating symp-
toms as per NACO-NACP III Algorithms for STI/RTI
(Fig. 2). Based on the symptoms listed in Fig. 2, tricho-
moniasis was reported in 289 patients out of 634 (46 %)
whereas based on PCR assay only (2 %) patients suffered
from T vaginalis infection alone and many patients had
coinfection (see Table 1). Similarly, infection with CT by
PCR assay amounts to only 7 % (42/634) while based on
SCM infection by CT is 20 % (128/634). Likewise large
proportions of false positives were also observed by SCM
for co-infections when compared with PCR based detec-
tion method (see Table 1). Coinfection of TV and Candida
and coinfection of CT, NG and Candida could not be
compared with PCR in the present study. Thus a huge
fraction of patients (83 %) were inaccurately diagnosed
using SCM for the three pathogens tested in this study
and all these patients were also given antibiotics leading to
huge overtreatment (see Fig. 3 and Table 1). Amongst
these misdiagnosed cases of trichomoniasis by SCM, 6
and 4 %, were actually infected with CT and NG re-
spectively while 2 % & ≤ 1 % were co-infected with CT
and CT+ NG respectively (Table. 1). It is pertinent to
mention here that a substantial population of patients
remained undiagnosed for the actual infecting microbe.
In order to find out which reproductive age group is
most vulnerable to T. vaginalis infection, the samples
collected from patients in different age groups 18–25,
Fig. 1 Proposed pre-packed STI/RTI kits under NACP III for syndromic case management procured by NACO/SACS, Ministry of Health and Family
Welfare, August 2007 (NACO-NACP III Algorithms for STI/RTI used by Clinicians)
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Fig. 2 NACO-NACP III Algorithms for STI/RTI used by Clinician
Table 1 Tabular presentation of infection using SCM and PCR assays
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26–35, 36–45, 46–55 and >55 years were compared based
on the diagnosis by PCR and also SCM. The distribution
of T. vaginalis infection complaints among all the age
groups was similar based on SCM as well PCR as reported
by others [18, 38, 39]. In both PCR and SCM, infection
with T. vaginalis is most prevalent (25–35 %) in the age
groups of 26–35 years and 36–45 years (see Fig. 4). Using
the clinical symptoms for syndromic management, we also
tried to find out how strongly the symptoms are associated
with infection. Amongst these samples and based on syn-
dromic approach, we observed significant association of
Trichomonas infection with patients having purists and
itching (19 %), lower abdominal pain (17 %), dysuria and
dyspareunia (15 %), foul smelling discharge (12 %), fre-
quency of micturition (11 %), vaginitis (10 %), cervicitis
(7 %), irregular bleeding (5 %) and pain during intercourse
(4 %). Using PCR based diagnostic assay the percent symp-
toms associated with T. vaginalis infected patients were;
lower abdominal pain (21 %), itching (18 %), foul smelling
discharge (14 %), vaginitis (12 %), dysuria (11 %), cervicitis
(9 %), pain during intercourse (7 %), frequency of mictur-
ition (5 %) and irregular bleeding (3 %). As is evident from
these results, irrespective of the diagnostic method used,
the pattern of symptoms remain similar in the infected
population, however, none of the symptoms was signifi-
cantly or categorically specific to the disease (see Fig. 5).
The maximum association of any symptom was about
20 % whether it is itching or lower abdominal pain.
Discussion
The burden of trichomoniasis in poor resource settings
and high-risk groups of industrialized settings in devel-
oping countries is soaring due to lack of accurate and
confirmed diagnosis [40]. SCM of the disease has several
limitations including overtreatment of symptomatic pa-
tients. In addition, high rate of asymptomatic infection
in male partners of infected females and subsequent re-
infection have significant implications in the control and
management program for STI [25, 41]. In India, Govern-
ment hospitals and peripheral laboratories continue to
Fig. 3 Bar diagram showing percent misdiagnosis and overtreatment based on comparison of SCM and PCR assays. The patients were classified
as infected for TV, CT and NG based on definite diagnosis by PCR and symptom based diagnosis by SCM (See Table 1). All patients were given
antibiotics based on SCM. Overtreatment and misdiagnosis by SCM for infection and coinfection with TV, CT and NG were calculated by
comparing with PCR results
Fig. 4 Age wise distribution of Trichomonas vaginalis infection among symptomatic women visiting the OPD of Obstetrics & Gynecology
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characterize and manage the STI using syndromic ap-
proach [42–46]. The existing standard protocol used for
detection is pelvic examination (adolescent women),
microscopic detection and wet mount in clinical setups
[47–49]. Since wet mount is reported to be approxi-
mately 50–60 % sensitive, it limits accurate and con-
firmed detection of trichomoniasis [50–54]. The Point of
Care test, such as OSOM, InPouchTV, lateral flow strip
test, TMA and other rapid tests (vaginal pH and the
presence of amines) are also not sufficiently sensitive for
confirmed detection [21, 55–62]. The introduction of
PCR based diagnostics has enhanced our understanding
of the epidemiology of T. vaginalis. However, due to
high cost of imported kits, the NAAT-based assays are
not commonly used in India. The present study was
undertaken to establish the need of diagnosis-based
treatment of trichomoniasis by comparing the percent-
age of patients who were genuinely infected, as evident
by PCR based diagnostics, and those diagnosed based on
symptoms using SCM approach. Our results clearly es-
tablish that the SCM is imprecise and results in enor-
mous overtreatment of patients. This may contribute to
the development of resistance to common antibiotics.
The effective treatment available against trichomonia-
sis makes it one of the most curable STIs but undiag-
nosed and untreated infections may serve as a reservoir
for spreading the infection and opportunistic infection
by other STIs. The long term serious consequences in-
cluding pelvic inflammatory disease, preterm births or
low-birth-weight of infants are also associated with poor
diagnosis. WHO developed a simplified tool (a flowchart or
algorithm) to guide health workers in the implementation
of syndromic management of STI for women with symp-
toms of vaginal discharge and/or lower abdominal pain (see
Figs. 1 and 2). However, it is important to recognize the
limitations of the vaginal discharge algorithms, particularly
in the management of cervical infection (Trichomoniasis,
gonococcal and Chlamydial infections). In the present
study, we observed a large number of false positives based
on symptoms and all these patients were given treatment
with one or more antibiotics as per pre-packed STI/RTI
kits procured by NACO/SACS, Ministry of Health and
Family Welfare, Govt of India under NACP III for diseases
management. The problem with syndromic management is
not only misdiagnosis but also overtreatment. Moreover,
often the patient is not given treatment for the actual
causative pathogen. The management of trichomoniasis
based on symptoms is therefore highly unreliable because
the spectrum of infection is broad and other STIs have
similar clinical presentations and it is difficult to differenti-
ate and characterize the causative agent by the routine clin-
ical observations (Fig. 5). In general, but especially in low
prevalence settings and in adolescent females, endogenous
vaginitis rather than STI is the main cause of vaginal dis-
charge [51]. While attempts have been made to increase
the sensitivity and specificity of the vaginal discharge algo-
rithm for the diagnosis of cervical infection through the
introduction of an appropriate, situation-specific risk as-
sessment, remain low in our studies as we did not observe
any symptom that was specifically associated with all TV
Fig. 5 Association of different symptoms in patients with Trichomonas vaginalis. Different symptoms observed in patients infected with T. vaginalis
based on SCM or PCR were plotted. As observed, none of the symptoms is uniquely associated with T. vaginalis infection as maximum association of
any symptom found in the patients is less than 20 % (PII = Purists & Itching Introits, LAP = Lower Abdominal Pain, FM = Frequency of Micturition,
FSGVD = Foul Smelling Greenish Vaginal Discharge, D&D = Dysuria & Dyspareunia)
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patients. The maximum association of any symptoms was
20 % which is too low an association to be used to classify
the cause of infection. Moreover, some of the risk assess-
ment questions based on demographics, low income,
illiteracy, religion, occupations, marital status and preg-
nancy tend to incorrectly classify too many adolescents to
be at risk of infection [6, 63–64]. Thus SCM is unsuitable
for routine clinical diagnosis of trichomoniasis even in re-
source poor countries. Consequently, there is a need to
identify the main trichomoniasis risk factors in women in
the local population and tailor the risk assessment accord-
ingly. It is equally important to develop and evaluate rapid,
specific and inexpensive tests to diagnose and control
trichomoniasis. The gold standard method for detection
of trichomoniasis in women is culture of vaginal swab
specimens. The drawback of culture is, requirement of
long duration of incubation for the growth of the organ-
ism, need for expert microbiologist and low sensitivity
compared to nucleic acid amplification tests (NAATs)
[15, 65]. The traditional clinical diagnostic methods fail
to identify more than one half of mixed infections which if
left untreated can result in adverse pregnancy outcomes
and exacerbated risk for both acquisition and transmission
of HIV [6, 66–69]. The currently available POC diagnostic
assays for T. vaginalis are promising but not as sensitive
as NAAT based assays [70–74]. Undoubtedly, there is an
urgent need to reduce the cost and complexity of NAAT-
based assay so that they can be performed in resource
poor settings in developing countries.
Conclusion
The study provides evidence to show that in spite of several
advantages of SCM of trichomoniasis, definite diagnosis
must be carried out before starting the treatment. SCM
purely relies on subjective judgment leading to misdiag-
nosis and overtreatment in infected patients. It may
results in developing antibiotic resistance. Moreover,
over-treatment and inaccurate diagnosis, based on syn-
dromic approach, is a large economic wastage.
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